Article
Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab.
Scientific reports - 24 Aug 2016
Nicolazzo Chiara, Raimondi Cristina, Mancini MariaLaura, Caponnetto Salvatore, Gradilone Angela, Gandini Orietta, Mastromartino Maria, Del Bene Gabriella, Prete Alessandra, Longo Flavia, Cortesi Enrico, Gazzaniga Paola
Abstract excerpt
Controversial results on the predictive value of programmed death ligand 1 (PD-L1) status in lung tumor tissue for response to immune checkpoint inhibitors do not allow for any conclusive consideration. Liquid biopsy might allow real-time sampling of patients for PD-L1 through the course of the disease. Twenty-four stage IV NSCLC patients included in the Expanded Access Program with Nivolumab were enrolled....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.